De Moor, Raf
Koroki, Yosuke
Wu, David Bin-Chia
Yu, Dae Young
Tohyama, Mikiko
Ohyama, Chikara
Funding for this research was provided by:
Janssen Pharmaceutical K.K
Article History
Received: 30 December 2022
Accepted: 13 April 2023
First Online: 28 April 2023
Declarations
:
: In this study, we used anonymized, data obtained from Japan Medical Data Vision Co., Ltd. Approval by an institutional review board and informed consent do not apply to the use of de-identified secondary data according to the Japanese ethical guidelines for medical and biological research involving human subjects (ExternalRef removed). To access the de-identified data, a license fee was paid to Japan Medical Data Vision Co., Ltd. All data processing was in compliance with the Declaration of Helsinki.
: Not applicable.
: Mikiko Tohyama: received consulting fees from Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Ono Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Maruho Co.,Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K., Nobelpharma Co., Ltd., Janssen Pharmaceutical K.K. Raf De Moor: employee of Janssen Pharmaceutical K.K. and holds stock in Johnson & Johnson. Yosuke Koroki: employee of Janssen Pharmaceutical K.K. and holds stock in Johnson & Johnson. David Bin-Chia Wu: received grant from Pfizer; employee of Janssen Asia Pacific and holds stock in Johnson & Johnson. Dae Young Yu: employee of Janssen Asia Pacific. Chikara Ohyama: payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co.,Ltd., Bayer Yakuhin, Ltd., Nippon Shinyaku Co., Ltd., AstraZeneca K.K., Sanofi K.K; Support for attending meetings and/or travel: Janssen Pharmaceutical K.K.; Participation on a Data Safety Monitoring Board or Advisory Board: Janssen Pharmaceutical K.K., Sanofi K.K.